酪酸梭菌和婴儿型双歧杆菌对霍乱弧菌的拮抗试验

了解酪酸梭菌和婴儿型双歧杆菌单独及混合培养时对霍乱弧菌的拮抗作用。将酪酸梭菌ＬＣＬ１６６和婴儿型双歧杆菌ＬＣＬ１７２分别与霍乱弧菌Ｏ１、Ｏ１３９单独和混合培养,定时对霍乱弧菌计数,并对菌数的对数进行在检验。两株菌混合培养时对霍乱弧菌的抑制效果基本相同,单独和混合培养时对霍乱弧菌的拮抗作用主要由酪酸梭菌引起,酪酸梭菌具有抑制霍乱弧菌的作用。     

酪酸梭菌与婴儿型双歧杆菌对产气荚膜梭菌试管内生物拮抗作用的研究

用酪酸权菌（Clostridium butyricum）和婴儿型双歧杆菌（Bifidobacterium Infantis）对产气荚膜梭菌（Clostriduim perfringens）进行试管内的生物拮抗试验。将酪酸梭菌、婴儿型双歧杆菌及酪酸梭菌和婴儿型双歧杆菌分别对产气荚膜酸菌以一定的比例等量混合接种于GAM液体培养基中进行厌氧培养。实验证明酪酸梭菌和婴儿型双歧能明显抑制产气荚膜梭菌的生长,并且比各自单独培养时显示了较强的生物拮抗作用。     

酪酸梭菌-婴儿型双歧杆菌二联活菌制剂的研究

对酪酸梭菌－婴儿型双歧杆菌二联活菌制剂的特性及功效进行研究和分析。方法：通过实验鼠进行刺激生长试验、活菌数测定、毒理试验、调节肠道菌群试验、免疫调节作用来观察制剂的作用。结果：小鼠肠道中双歧杆菌、乳杆菌、酪酸梭菌数量明显增加,高剂量能增加小鼠抗体生成细胞数。     

酪酸梭菌与婴双歧杆菌对艰难梭菌体外生物拮抗作用的作用

用酪酸梭菌（Clostridium butyricum)和婴双歧杆菌（Bifidobacterium infantis)单独或联合艰难菌（Clostridium difficile)进行试管内的生物拮抗作用,将酪酸梭菌、婴儿双歧杆菌单独或酪酸梭菌和婴儿双歧杆菌联合分别与艰难梭菌以一定的比例等量混合后,接种于GAM液体培养基中进行厌氧培养。证明酪酸梭菌和婴儿双歧杆菌能明显抑制艰难梭菌的生长,并且两菌联合比各自单独培养时显示出更强的生物拮抗作用。     

酪酸梭菌--婴儿型双歧杆菌二联活菌制剂对人体肠道菌群的调节试验

目的　观察酪酸梭菌——婴儿型双歧杆菌二联活菌制剂对受试人群肠道菌群的影响。方法　检测受试者服用前后的肠道菌群并计数。结果　肠杆菌、肠球菌、拟杆菌的数量无明显变化 ,双歧杆菌、乳杆菌的数量明显增加 ,差异有非常显著性 (P<0 .0 1) ,结论　酪酸梭菌——婴儿型双歧杆菌二联活菌制剂具有一定的调节人体肠道菌群、增殖双歧杆菌和乳杆菌的作用。     

酷酸梭菌——婴儿型双歧杆菌二联活菌制剂对人体肠道菌群的调节试验

目的 观察酷酸梭菌－－婴儿型双歧杆菌二联活菌制剂对受试人群肠道菌群的影响。方法 检测受试者服用前后的肠道菌群并计数。结果 肠杆菌、肠球菌、拟杆菌的数量无明显变化,双歧杆菌、乳杆菌的数量明显增加,差异有非常显著性（Ｐ〈０．０１）,结论 酪酸梭菌－－婴儿型双歧杆菌二联活菌制剂具有一定的调节人体肠道菌群、增殖双歧杆菌和乳杆菌的作用。     

肠易激综合征患者服用酪酸菌制剂前后肠道菌群状况

治疗ＩＢＳ,观察酪酸菌制剂的临床疗效及肠道菌群状况。从门诊随机选择２１例男性,９例女性。检测大便常见菌群和病原菌,采用Ｍｉｌｅｓ－Ｍｉｓｒｏ介绍的滴注法操作。每次培养时均选上述细菌标准菌株一同培养作质控。治疗前总厌氧菌、双歧杆菌和乳酸杆菌下降,而有潜在致病性的梭菌明显下降。无致病菌生长。治疗后腹泻次数明显减少。总有效率为８３４％,双歧杆菌和乳酸杆菌升高明显。结论：ＩＢＳ易致肠菌失调,酪酸菌能抑制肠道内腐败菌、病原菌,并能促进双歧杆菌、乳酸菌等肠道内的有益菌发育。     

酪酸梭菌-双歧杆菌二联活菌制剂对慢性腹泻患者肠道菌群的影响

给慢性腹泻病人口服酪酸梭菌-双歧杆菌二联活菌制剂,然后检测患者服药前后的肠道菌群变化.患者服用药品后,葡萄球菌、酵母菌、消化球菌、真杆菌和小梭菌的数量无明显变化,肠杆菌、肠球菌的数量明显减少,拟杆菌、双歧杆菌、乳杆菌的数量明显增加,其中肠球菌、肠杆菌、拟杆菌和双歧杆菌的变化有显著性(P﹤0.05),提示酪酸梭菌-双歧杆菌二联活菌制剂对慢性腹泻病人的肠道菌群具有明显的影响、具有增殖拟杆菌、双歧杆菌和乳杆菌的作用.     

酪酸梭菌二联活菌制剂治疗儿科不同类型腹泻的疗效观察

目的评估酪酸梭菌、婴儿型双歧杆菌二联活菌制剂治疗儿科最常见3种不同类型腹泻的疗效。方法选择2008年至2010年3年间合肥市第一人民医院儿科有腹泻症状的住院患者224例,采用随机数表法分为酪酸梭菌、婴儿型双歧杆菌二联活菌制剂治疗组110例,未加用或用加其他微生态制剂的对照组114例。2组的性别、年龄、病情相比较,差异无统计学意义(P>0.05)。结果酪酸梭菌、婴儿型双歧杆菌二联活菌制剂治疗组总有效率为95.5%,对照组为80.7%,差异有统计学意义(P<0.01)。2组治疗后的平均止泻时间为(2±1.45)d和(3.9±1.11)d,差异有统计学意义(P<0.05)。结论酪酸梭菌、婴儿型双歧杆菌二联活菌制剂治疗婴幼儿腹泻优于未加用或加用其他微生态制剂,且未见明显不良反应。     

酪酸梭菌的研究与应用进展

酪酸梭菌属于微生态制剂,酪酸梭菌具有抑制肠出血性大肠埃希菌、痢疾志贺菌、霍乱沙门菌、霍乱弧菌等肠道致病菌的生长繁殖,抑制艰难梭菌生长繁殖,促进双歧杆菌、乳酸菌等肠道有益菌的生长繁殖,加强肠道黏膜膜营养代谢、保护受损的黏膜屏障,激活免疫细胞、改善并恢复肠道正常免疫力,防治肿瘤的生长的作用.所以酪酸梭菌制剂对腹泻、肠炎、肠易激综合征、结直肠癌新生儿黄疸等疾病都有很强的防治作用.     

对双歧杆菌DM9227株的实验研究 Ⅲ.双歧杆菌DM9227株与蜡样芽胞杆菌DM423株共生关系的初步研究

本文对厌氧的双歧杆菌DM9227株与需氧的蜡样芽胞杆菌DM423株的共生关系进行了初步研究。将DM9227株与DM423株分别单独及按一定比例等量混合接种于BS肉汤内进行培养,间隔一定时间检测两菌在培养基内菌数的消长情况。结果表明DM423株与DM9227株之间呈偏生关系,即DM423株对DM9227株有促进作用,且在两菌比例适宜(1:100)情况下促进作用更明显,而DM9227株对DM423株有抑制作用。进一步将接种DM423株的Nb琼脂平板与接种DM9227株的BS琼脂平板在普通环境下一起密闭培养,可见厌氧的DM9227株生长良好,提示DM423株可能是通过消耗氧气,降低培养基的Eh,从而促进DM9227株生长的。     

Factors controlling acid tolerance of Listeria monocytogenes: effects of nisin and other ionophores.

The acid tolerance of a Listeria monocytogenes serotype 4b strain was studied by measuring its ability to survive at an acidic pH at 37 degrees C. The acid tolerance of L. monocytogenes was much lower than those of Escherichia coli O157:H7 and Shigella flexneri strains. This observation suggested a higher infective dose for L. monocytogenes than E. coli O157:H7 and Shigella. The susceptibility of L. monocytogenes to acidic pH was dependent upon growth medium pH and growth phase of the culture. Nisin and some other ionophores reduced the acid tolerance of both stationary-phase and log-phase cultures of L. monocytogenes. These studies indicated that nisin might be a useful candidate for controlling acid tolerance of L. monocytogenes.     

The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice

Enterohemorrhagic Escherichia coli (EHEC) O157:H7 has been considered as an agent responsible for outbreak of hemorrhagic colitis and the hemolytic uremic syndrome. We examined the effect of the probiotic agent Clostridium butyricum MIYAIRI strain 588 on EHEC O157:H7 infections in vitro and in vivo using gnotobiotic mice. The growth of EHEC O157:H7 and the production of Shiga-like toxins in broth cultures were inhibited by co-incubation with C. butyricum. The antibacterial effects of butyric and lactic acid were demonstrated in a dose-dependent manner. In addition, the inhibitory effect of butyric acid on the viability of EHEC was demonstrated not only at low pH, but also at neutral pH adjusted to 7.0. Flowcytometric analysis showed that pre-incubation of Caco-2 cells with C. butyricum and E. coli K12 inhibited the adhesion of EHEC O157:H7. However, the effect of C. butyricum on adhesion of EHEC to Caco-2 cells was more inhibitory than that of E. coli K12. Gnotobiotic mice mono-associated with EHEC O157:H7 died within 4-7 days after the infection. On the other hand, all gnotobiotic mice prophylactically pre-treated with C. butyricum survived exposure to EHEC O157:H7 and of the gnotobiotic mice therapeutically post-treated with C. butyricum, 50% survived. Both counts of EHEC O157:H7 and the amounts of shiga-like toxins (Stx1 and Stx2) in fecal contents of gnotobiotic mice di-associated with EHEC O157:H7 and C. butyricum were less than those of gnotobiotic mice mono-associated with EHEC O157:H7. These results indicated that the probiotic bacterium C. butyricum MIYAIRI strain 588 has preventive and therapeutic effects on EHEC O157:H7 infection in gnotobiotic mice.     

对双歧杆菌DM9227株的实验研究——Ⅰ.双歧杆菌DM9227株的试管内生物拮抗作用的研究

本文对由健康婴儿分离的双歧杆菌DM9227株进行了试管内的生物拮抗试验。将双歧杆菌DM9227株分别与金黄色葡萄球菌、产毒性大肠杆菌及侵袭性大肠杆菌以一定的比例等量混合接种于PYG液体培养基中进行厌氧培养。试验证明双歧杆菌DM9227株能明显抑制上述3种细菌的生长繁殖,显示出较强的生物拮抗作用。拮抗机制可能与双歧杆菌DM9227株能产生一定量的醋酸和乳酸,降低培养基的pH,从而抑制该3种菌的生长有关。     

Escherichia coli O157:H7 becomes resistant to sodium chlorate in pure culture, but not in mixed culture or in vivo

AIMS: Chlorate kills Escherichia coli O157:H7 and may be an effective feed additive for use in food animals. This study was designed to determine if development of chlorate-resistant E. coli O157:H7 strains was likely. METHODS AND RESULTS: Escherichia coli O157:H7 was chlorate-sensitive, but became chlorate-resistant in pure batch culture and in sterilized faecal fluid; it was killed in mixed culture and did not become resistant. Addition of chlorate to continuous pure cultures caused chlorate resistance, but chlorate addition to mixed continuous culture eliminated E. coli O157:H7 and no resistance occurred. Piglets challenged with E. coli O157:H7 were treated with chlorate; populations were reduced and colonies were always chlorate-sensitive. CONCLUSION: Chlorate-resistant E. coli O157:H7 can be selected in pure, but not mixed culture, and results suggest that terminal chlorate feeding will not select for chlorate-resistance in vivo. SIGNIFICANCE AND IMPACT OF THE STUDY: Chlorate can reduce food-borne pathogens prior to harvest, but development of resistance does not appear likely in vivo.     

Inactivation of Escherichia coli O157:H7 in simulated human gastric fluid

Human disease caused by Escherichia coli O157:H7 is a function of the number of cells that are present at potential sites of infection and host susceptibility. Such infectious doses are a result, in part, of the quantity of cells that are ingested and that survive human host defenses, such as the low-pH environment of the stomach. To more fully understand the kinetics of E. coli O157:H7 survival in gastric fluid, individual E. coli O157:H7 strains were suspended in various media (i.e., saline, cooked ground beef [CGB], and CGB containing a commercial antacid product [CGB+A]), mixed at various proportions with simulated human gastric fluid (SGF), and then incubated at 37 degrees C for up to 4 h. The highest inactivation rate among nine E. coli O157:H7 strains was observed in saline. Specifically, the average survival rates in 100:1 and 10:1 proportions of SGF-saline were -1.344 +/- 0.564 and -0.997 +/- 0.388 log(10) CFU/h, respectively. In contrast, the average inactivation rate for 10 E. coli O157:H7 strains suspended in 10:1 SGF-CGB was -0.081 +/- 0.068, a rate that was 12-fold lower than that observed for SGF-saline. In comparison, the average inactivation rate for Shigella flexneri strain 5348 in 100:1 and 10:1 SGF-saline was -8.784 and -17.310, respectively. These latter inactivation rates were 7- to 17-fold higher than those for E. coli O157:H7 strains in SGF-saline and were 4-fold higher than those for E. coli O157:H7 strains in SGF-CGB. The survival rate of E. coli O157:H7 strain GFP80EC increased as the dose of antacid increased from one-half to twice the prescribed dose. A similar trend was observed for the matrix pH over the range of pH 1.6 to 5.7, indicating that pH is a primary factor affecting E. coli O157:H7 survival in SGF-CGB+A. These results can be used in risk assessment to define dose-response relationships for E. coli O157:H7 and to evaluate potential surrogate organisms.